Internal Medicine, Pulmonary Disease · Houston, TX
NPI
1669602710
Since 2009
Specialty
Internal Medicine, Pulmonary Disease
Code 207RP1001X
Group practices
4
Medicare group memberships
Hospitals
5
Hospital affiliations
6550 Fannin St, Suite 1101
Houston, TX, 77030
Phone (713) 441-0006
Groups this clinician bills Medicare through
Medicare paid, 2024
$62K
580 services
Medicare patients, 2024
199
Average age 71
Drug cost, 2024
$29.0M
3,037 prescriptions
Company payments, 2025
$105K
From 11 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Sandeep Sahay was code 99233 (hospital e&m - subsequent), 210 times for 59 patients. In total Sandeep Sahay billed 580 services in 18 codes, and Medicare paid $62K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2016-11-30.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99233 Hospital E&M - Subsequent | Facility | 210 | 59 | $93.12 | $20K |
| 99215 Office E&M - Established | Facility | 156 | 108 | $110.65 | $17K |
| 99214 Office E&M - Established | Facility | 35 | 33 | $75.38 | $2,638 |
| 99223 Hospital E&M - Initial | Facility | 29 | 26 | $138.08 | $4,004 |
| 99214 Office E&M - Established | Office | 25 | 23 | $96.65 | $2,416 |
| 99205 Office E&M - New | Facility | 23 | 23 | $145.53 | $3,347 |
| 99204 Office E&M - New | Facility | 15 | 15 | $103.20 | $1,548 |
| 99215 Office E&M - Established | Office | 12 | 11 | $145.01 | $1,740 |
By year: 2022 $77K for 798 services; 2023 $55K for 572 services; 2024 $62K for 580 services.
Medicare prescription drug claims, 2024
In 2024, the drug Sandeep Sahay prescribed most often to Medicare patients was Opsumit (Macitentan), with 660 prescriptions and refills. In total Sandeep Sahay wrote 3,037 Medicare prescriptions that cost $29.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Opsumit Macitentan | 660 | 660 | 76 | $8.4M |
| Adempas Riociguat | 393 | 393 | 39 | $5.3M |
| Tadalafil Generic | 281 | 367 | 44 | $338K |
| Uptravi Selexipag | 273 | 281 | 26 | $6.2M |
| Orenitram Er Treprostinil Diolamine | 133 | 133 | Under 11 | $2.0M |
| Furosemide Generic | 120 | 300 | 46 | $974 |
| Tyvaso Dpi Treprostinil | 109 | 109 | 12 | $2.6M |
| Ambrisentan Generic | 107 | 115 | 11 | $350K |
| Sildenafil Citrate Generic | 97 | 203 | 33 | $49K |
| Spironolactone Generic | 87 | 253 | 32 | $1,174 |
| Letairis Ambrisentan | 67 | 81 | Under 11 | $1.1M |
| Ofev Nintedanib Esylate | 57 | 59 | Under 11 | $755K |
| Winrevair Sotatercept-Csrk | 54 | 54 | 14 | $839K |
| Eliquis Apixaban | 43 | 106 | 13 | $58K |
| Digoxin Generic | 38 | 110 | 12 | $1,396 |
Brand drugs: 2,022 claims; generic drugs: - claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Sandeep Sahay $105K ($105K in general payments such as food, travel and fees) from 11 companies. The largest payer was Merck Sharp & Dohme LLC with $90K.
| Company | Payments | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC MRK | 62 | $90K |
| United Therapeutics Corporation UTHR | 24 | $11K |
| Actelion Pharmaceuticals US, Inc. JNJ | 3 | $2,954 |
| Liquidia Technologies, Inc. | 5 | $253 |
| GlaxoSmithKline, LLC. GSK | 10 | $221 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $93.59 |
| Insmed, Inc. INSM | 3 | $63.07 |
| Regeneron Healthcare Solutions, Inc. REGN | 1 | $25.62 |
| Sandoz Inc. SDZ.SW | 1 | $22.47 |
| Grifols USA, LLC | 1 | $19.23 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.